



CURRICULUM VITAE

SIGNATURE:		DATE:	
NAME: TITLE:	Jamison Feramisco, MD, PhD	DATE UPDATED:	Feb 2020

RESEARCH SITE NAME/ ADDRESS:

Main Site ACRC Studies 6280 Jackson Drive, Suite 8 San Diego, California 92119	Office: (619) 464.1607 Ext. 136 Fax: (619) 303.0559 Email: drferamisco@mdsrsandiego.com
----------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
GCP Training	Certificate	2019	Good Clinical Practices
University of California at San Francisco	Fellowship	2010 - 2011	Molecular Medicine
University of California at San Francisco	Residency	2008 - 2010	Dermatology
University of Texas Southwestern Medical Center at Dallas and Parkland Hospital	Internship	2007 - 2008	Internal Medicine
University of Texas Southwestern Medical Center at Dallas	MD	2000 - 2007	MD/PhD
University of California at Los Angeles	BS	1996 - 2000	Microbiology and Molecular Genetics

POSITIONS AND EMPLOYMENT:

2019 – Present	ACRC Studies - Investigator
2019 - Present	MD Strategies Research Centers – Investigator
2019 - Present	San Diego Center for Family Health - Dermatology and Skin Surgery Institute, Chief Medical Officer, San Diego, California
2010 - Present	Colusa Regional Medical Center and Colusa Indian Health Clinic Rural Health Clinic and Federally Qualified Health Center Dermatology and Wound Care - Founding Physician and Director.
2014 - Present	Advanced Healthcare Solutions, Dallas, Texas. Chief Medical Officer
2014 - 2019	Third Eye Health Inc. Co-Founder/ Chief Medical Officer
2014 - 2018	San Mateo Medical Center. San Mateo, California Attending Physician Dermatology and Wound Care
2008 - 2014	Kentfield Rehabilitation Hospital, Marin Medical Group, Marin, California Attending Physician -Dermatology and Wound Care/ Hospitalist in Internal Medicine
2009 - 2013	Knight MD Inc. Telemedicine Founder and Chief Executive Officer
2011 - 2013	DermLink Inc. Chief Operating Officer and Chief Medical Officer, Co-founder Dermatology Provider
2011 - 2012	Care Meridian Granite Bay (Sub-acute Care Facility) Medical Director and Wound Granite Bay, California. Care Director
2010 - 2010	Country Villa Healthcare Center, San Rafael, California Director, Dermatology and Wound Care Program

CLINICAL RESEARCH EXPERIENCE:

Publications P2P Reviewed

Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nat Genet.* 2000 Feb;24(2): 132-8.

Kabarowski JH, Feramisco JD, Le LQ, Gu JL, Luoh SW, Simon MJ, Witte ON. Direct genetic demonstration of G alpha 13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement. *Proc Natl Acad Sci US A.* 2000 Oct 24;97(22): 12109-14.

Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. *Mol Cell.* 2002 Aug; 10(2):237-45.

Feramisco JD, Goldstein JL, Brown MS. Membrane topology of human Insig-1, a protein regulator of lipid synthesis. *J Biol Chem.* 2004 Feb 27;279(9):8487-96.

Adams CM, Reitz J, DeBrabander JK, Feramisco JD, Li L, Brown MS, Goldstein JL. Cholesterol and 25-Hydroxycholesterol inhibit activation of SREBP's by different mechanisms, both involving SCAP and Insigs. *J Biol Chem.* 2004 Dec 10;279(50):52772-80.

Feramisco JD, Radhakrishnan A, Ikeda Y, Reitz J, Brown MS, Goldstein JL. Intramembrane aspartic acid in SCAP protein governs cholesterol-induced conformational change. *Proc Natl Acad Sci US A.* 2005 Mar 1; 102(9):3242-7.

Bell CL, Feramisco JD, Rogers JH and Provost DA. Reversal of Roux-en-Y gastric bypass: indication technique, and outcomes. *Surgery for Obesity and Related Diseases*, Volume 2, Issue 3, May-June 2006, 309.

Feramisco JD, Cayce RL, Tsao H. Recent updates on genetics: teaching old dogmas new tricks. *Pediatric Dermatology.* 2008 Jan-Feb;25(1):99-108.

Feramisco JD, Larsen F, Weitzel SB, Cockerell CJ, and Ghali FE. Congenital atrophic dermatofibrosarcoma protuberans in a 7-month old boy treated with Mohs micrographic surgery. *Pediatric Dermatology.* 2008 Jul-Aug;25(4):455-9.

Lee JN, Zhang X, Feramisco JD, Gong Y, Ye J. Unsaturated fatty acids inhibit proteasomal degradation of Insig-1 at a postubiquitination step. *J Biol Chem.* 2008 Nov 28;283(48):33772-83.

Feramisco JD, Leitenberger JJ, Redfern SI, Bian A, Xie XJ, Resneck JS Jr. A gender gap in the dermatology literature? Cross-sectional analysis of manuscript authorship trends in dermatology journals during 3 decades. *J Am Acad Dermatol.* 2009 Jan;60(1):63-9.

Feramisco JD, Sadreyev RI, Murray M, Grishin NV, Tsao H. Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. *J Invest Dermatol.* 2009 Nov;129(11):2628-36.

Sadreyev RI, Feramisco JD, Tsao H, Grishin V. Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways. *Bioinformatics*. 2009 Nov;25(22):2891-6.

Feramisco JD, Sulk M, Buddenkotte J, Ikoma A, Cevikas F, Seeliger S, Voegel J, Aubert J, LeBoit P, Basbaum A, Julius DJ, Steinhoff M. Immunohistochemical localization and expression levels of transient receptor potential ion channels (TRP) in human skin and patients with pruritic skin disease. *Acta Dermato Venereologica*. 2009 Vol. 89(6):711.

Research Experience – Investigator

Leo Pharma: An open-label, multi-center drug-drug interaction trial to investigate the effects of XXXX on the pharmacokinetics of selected cytochrome P450 (CYP) substrates in adult subjects with moderate-to-severe atopic dermatitis – ECZTRA 4

Incyte: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

Leo-Pharma: Long-term extension trial in subjects with atopic dermatitis who participated in previous tralokinumab trials – ECZTEND

Dermira: A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis